Therefore, our in vivo validation that miR-29 is a tumor suppressive miRNA in melanoma might contribute to the development of new therapeutic approaches, not only targeting MAFG or MYBL2, but also miR-29 itself. Here, MYBL2 is linked to neoplasm.